Neurofeedback Treatment on Depressive Symptoms and Functional Recovery in Treatment-Resistant Patients with Major...

Area of Science:

• Neuroscience
• Psychiatry
• Clinical Psychology

Background:

• Treatment-resistant depression (TRD) presents significant challenges in achieving remission.
• Augmentation strategies are crucial for improving outcomes in TRD patients.
• Neurofeedback is explored as a potential non-pharmacological intervention.

Purpose of the Study:

• To evaluate the efficacy of neurofeedback as an augmentation treatment for depressive symptoms.
• To assess the impact of neurofeedback on functional recovery in TRD patients.
• To compare neurofeedback augmentation with medication-only treatment.

Main Methods:

• A randomized controlled trial involving 24 TRD patients and 12 healthy controls.
• TRD patients were assigned to either neurofeedback augmentation or medication-only (TAU) groups.
• Standardized scales (HAM-D, BDI, CGI-S, EQ-5D-5L, SDS) were used for assessments over 12 weeks.

Main Results:

• Neurofeedback significantly reduced depression scores (HAM-D, BDI-II, CGI-S, SDS) and improved quality of life (EQ-5D-5L).
• Response and remission rates in the neurofeedback group were 58.3% and 50.0%, respectively.
• Greater improvements in HAM-D, EQ-5D-5L, and SDS were observed in the neurofeedback group compared to TAU.

Conclusions:

• Neurofeedback shows promise as an effective augmentation strategy for TRD.
• The treatment not only alleviates depressive symptoms but also enhances functional recovery.
• Further research with larger sample sizes is warranted to confirm these findings.